APA (7th ed.) Citation

M, W., A, R., F, E., K, M., M, T., & J, D. (2026). Second-line treatment with tafasitamab and lenalidomide for relapsed/refractory primary cutaneous diffuse large B-cell lymphoma. Leukemia & lymphoma, 67(9), 1990. https://doi.org/10.1080/10428194.2026.2672106

Chicago Style (17th ed.) Citation

M, Wobser, Rosenwald A, Eisele F, Maurus K, Topp M, and Duell J. "Second-line Treatment with Tafasitamab and Lenalidomide for Relapsed/refractory Primary Cutaneous Diffuse Large B-cell Lymphoma." Leukemia & Lymphoma 67, no. 9 (2026): 1990. https://doi.org/10.1080/10428194.2026.2672106.

MLA (9th ed.) Citation

M, Wobser, et al. "Second-line Treatment with Tafasitamab and Lenalidomide for Relapsed/refractory Primary Cutaneous Diffuse Large B-cell Lymphoma." Leukemia & Lymphoma, vol. 67, no. 9, 2026, p. 1990, https://doi.org/10.1080/10428194.2026.2672106.